Who Paid My Doc
Philip Basala
Urogynecology and Reconstructive Pelvic Surgery Keyser, WV Doctor of Osteopathy
NPI 1558376137 CMS profile 297153
Potomac Valley Hospital, 100 Pin Oak Lane, Keyser, WV 26726
General payments
$4,042
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Philip Basala of Keyser, WV is reported in the CMS Open Payments database as having received $4,042 across 262 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 57th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $49 | 2 | |
| 2024 | General | $932 | 4 | |
| 2023 | General | $160 | 3 | |
| 2022 | General | $160 | 9 | |
| 2021 | General | $891 | 73 | |
| 2020 | General | $711 | 65 | |
| 2019 | General | $1,140 | 106 |
Beside peers
- Philip Basala
- Urogynecology and Reconstructive Pelvic Surgery median
- Middle half of Urogynecology and Reconstructive Pelvic Surgery
- National median
In program year 2025, general payments to Philip Basala were reported at $49. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.
Show as a table
| Year | Philip Basala | Urogynecology and Reconstructive Pelvic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,140 | $358 | $132–$1,270 | $163 |
| 2020 | $711 | $198 | $86–$642 | $114 |
| 2021 | $891 | $361 | $118–$1,182 | $132 |
| 2022 | $160 | $410 | $128–$1,175 | $149 |
| 2023 | $160 | $434 | $152–$1,344 | $160 |
| 2024 | $932 | $494 | $193–$1,331 | $164 |
| 2025 | $49 | $412 | $133–$1,300 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
85
Drug cost
$14,341
Branded share of claims
34.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 17 | $11,542 | |
| Estradiol | Generic | 25 | $1,461 | |
| Solifenacin Succinate | Generic | 31 | $1,212 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 12 | $126 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Records
262 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urogynecology and Reconstructive Pelvic Surgery in West Virginia
Related records
Urogynecology and Reconstructive Pelvic Surgery in West Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Urogynecology and Reconstructive Pelvic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in West Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.